Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 7
Submit an article Journal homepage
142
Views
7
CrossRef citations to date
0
Altmetric
Theme: Urological Cancer - Review

Current, new and novel therapy for castration-resistant prostate cancer

Josep M Gaya Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Spain; Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Spain
,
Youness Ahallal Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Rafael Sanchez-Salas Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Eric Barret Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Francois Rozet Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Marc Galiano Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Peter Macek Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Matthieu Durand Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Jennifer Cerruti Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Dominique Prapotnich Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
,
Stanislas Ropert Department of Oncology, Institut Montsouris, Paris, France; Department of Oncology, Institut Montsouris, Paris, France
,
Mostefa Bennamoun Department of Oncology, Institut Montsouris, Paris, France; Department of Oncology, Institut Montsouris, Paris, France
&
Xavier Cathelineau Department of Urology, Institut Montsouris, Paris, France; Department of Urology, Institut Montsouris, Paris, France
 show all
Pages 819-827 | Published online: 10 Jan 2014

References

  • Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16(3), 481–488 (2005).
  • Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA. Cancer J. Clin. 58(2), 71–96 (2008).
  • Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317(15), 909–916 (1987).
  • Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol. 5(10), 1555–1584 (2009).
  • Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168(1), 9–12 (2002).
  • Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr. Opin. Oncol. 21(3), 260–265 (2009).
  • Murat FJ, Poissonnier L, Rabilloud M et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol. 55(3), 640–647 (2009).
  • Scher HI, Halabi S, Tannock I et al.; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148–1159 (2008).
  • Scher HI, Beer TM, Higano CS et al.; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet 375(9724), 1437–1446 (2010).
  • Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: long-term results of MRC PR04 & PR05. Genitourinary Cancers Symposium Abstract 6 (2009).
  • Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57(2), 229–233 (1997).
  • Stapleton AM, Timme TL, Gousse AE et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin. Cancer Res. 3(8), 1389–1397 (1997).
  • Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11(13), 4653–4657 (2005).
  • Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66(5), 2815–2825 (2006).
  • Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur. Urol. 39(2), 121–130 (2001).
  • Lee DJ, Cha EK, Dubin JM et al. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int. 109(7), 968–985 (2012).
  • Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol. 61(3), 549–559 (2012).
  • Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 25(25), 3965–3970 (2007).
  • Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 98(8), 516–521 (2006).
  • Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21(7), 1232–1237 (2003).
  • Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925–4935 (2005).
  • Sonpavde G, Pond GR, Berry WR et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol. Oncol. 30(5), 607–613 (2012).
  • Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 13(21), 6396–6403 (2007).
  • Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol. 20(19), 3972–3982 (2002).
  • de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302–6309 (2008).
  • Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J. Clin. Oncol. 29(27), 3695–3704 (2011).
  • Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756–1764 (1996).
  • Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a Phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur. Urol. 44(5), 519–526 (2003).
  • Saad F, Gleason DM, Murray R et al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458–1468 (2002).
  • Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17(8), 2506–2513 (1999).
  • Tannock IF, de Wit R, Berry WR et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).
  • Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann. Oncol. 19(10), 1749–1753 (2008).
  • Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004).
  • Nelson JB, Fizazi K, Miller K et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118(22), 5709–5718 (2012).
  • Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137–2143 (2010).
  • Kantoff PW, Higano CS, Shore ND et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  • Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670–3679 (2009).
  • Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089–3094 (2006).
  • Nelson WG, Haffner MC, Yegnasubramanian S. Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids. Cancer Cell 20(1), 7–9 (2011).
  • Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N. Engl. J. Med. 364(21), 2055–2058 (2011).
  • Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26(28), 4563–4571 (2008).
  • Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28(9), 1496–1501 (2010).
  • Morgans AK, Smith MR, O’Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer 119(4), 863–870 (2013).
  • de Bono JS, Oudard S, Ozguroglu M et al.; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010).
  • Scher HI, Beer TM, Higano CS et al.; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet 375(9724), 1437–1446 (2010).
  • Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
  • Saad F, Gleason DM, Murray R et al.; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 96(11), 879–882 (2004).
  • Fizazi K, Carducci M, Smith M et al. Denosumab versus Zoledronic acid for treatment of bone metastases in men with castration-resistant préstate cancer: a randomised, double-blind study. Lancet 144, 646–674 (2011).
  • Agus DB, Stadler WM, Shevrin DH et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration resistant prostate cancer (mCRPC): updated data from a Phase I/II study. Proceedings of the ASCO Meeting, Chicago, IL, USA, June 2011 [Abstracts 29].
  • Parker C, Nilsson S, Heinrich D et al. Updated analysis of the Phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J. Clin. Oncol. 30(Suppl.), LBA4512 (2012).
  • O’Mahony D, Morris JC, Quinn C et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 13(3), 958–964 (2007).
  • Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099–1105 (2010).
  • Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137–2143 (2010).
  • Michaelson MD. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street? Cancer 118(7), 1744–1746 (2012).
  • Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 21(2), 319–324 (2010).
  • Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31(4), 412–419 (2013).
  • Pili R, Häggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol. 29(30), 4022–4028 (2011).
  • Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995).
  • Carducci MA, Saad F, Abrahamsson PA et al.; Atrasentan Phase III Study Group Institutions. A Phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110(9), 1959–1966 (2007).
  • James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, Phase 2 trial. Eur. Urol. 55(5), 1112–1123 (2009).
  • Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6(5), 1655–1663 (2000).
  • Chi KN, Hotte SJ, Yu EY et al. Randomized Phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(27), 4247–4254 (2010).
  • Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22(4), 337–358 (2003).
  • Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15(23), 7421–7428 (2009).
  • Araujo JC, Mathew P, Armstrong AJ et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a Phase 1–2 study. Cancer 118(1), 63–71 (2012).
  • Araujo JC, Trudel GC, Saad F et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized Phase III READY trial. J. Clin. Oncol. 31(Suppl. 6), Abstract LBA8 (2013).
  • Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 54(7), 1807–1811 (1994).
  • Tagawa ST, Milowsky MI, Morris MJ et al. Phase II trial of 177 Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177 Lu-J591) in patients with metastatic castrate-resistant prostate cancer (metCRPC). Clin. Oncol. 26, 5140 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.